Greenwich rises on immune response data from breast cancer therapy trial

Shares of cancer therapy developer Greenwich LifeSciences GLSI.O rise 18.8% to $11 premarket

GLSI says its experimental therapy, GLSI-100, to prevent breast cancer recurrences showed an increased immune response over time in patients during a late-stage study

The therapy creates an immune response over time, as measured by the increasing injection site reactions with increased vaccinations

Company says in the preliminary data, the patients reported immune response increased over time from baseline through the 4th- to 6th-month vaccinations

As of last close, stock has fallen 51.4% in the past 12 months